Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | Director | January 02, 2026 | January 07, 2026 |
| Histogen Inc.HSTO · Entity 112047 | Director · President and CEO | March 10, 2023 | March 14, 2023 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 11, 2018 | June 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dermata Therapeutics, Inc.
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2036-01-01 | Direct | 2,500 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,500 · Balance 2,500 F1: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date.
Histogen Inc.
Report date March 10, 2023 · Filed March 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2033-03-10 | Direct | 158,055 |
Reported balance
After 2023-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-10 · Grant · Acquired 158,055 · Balance 158,055 F1: 1/4 of the shares subject to the option vest one year after the date of grant, on 3/10/2024, and the remaining 1/36 of the shares vest on a monthly basis thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2033-03-10 | Direct | 55,532 |
Reported balance
After 2023-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-10 · Grant · Acquired 55,532 · Balance 55,532 F1: 1/4 of the shares subject to the option vest one year after the date of grant, on 3/10/2024, and the remaining 1/36 of the shares vest on a monthly basis thereafter. F2: The shares subject to this option are subject to forfeiture in the event that the shares available pursuant to the Issuer's 2020 Incentive Award Plan are not increased prior to the one-year anniversary and vesting of the award by an amount required to be available for issuance for all outstanding stock awards containing this forfeiture condition. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60 · Expires 2031-11-08 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 18,892 · Balance 0 F3: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share. F4: On March 10, 2023, the Issuer and the Reporting Person agreed to cancel the stock option award. F5: 1/4 of the shares subject to the option vested one year after the date of grant, on 11/8/2022, and the remaining 1/36 of the shares vest on a monthly basis thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2032-02-24 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 7,582 · Balance 0 F3: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share. F4: On March 10, 2023, the Issuer and the Reporting Person agreed to cancel the stock option award. F6: 1/4 of the shares subject to the option vested one year after the date of grant, on 2/24/2023, and the remaining 1/36 of the shares vest on a monthly basis thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4 of the shares subject to the option vest one year after the date of grant, on 3/10/2024, and the remaining 1/36 of the shares vest on a monthly basis thereafter.
F2: The shares subject to this option are subject to forfeiture in the event that the shares available pursuant to the Issuer's 2020 Incentive Award Plan are not increased prior to the one-year anniversary and vesting of the award by an amount required to be available for issuance for all outstanding stock awards containing this forfeiture condition.
F3: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share.
F4: On March 10, 2023, the Issuer and the Reporting Person agreed to cancel the stock option award.
F5: 1/4 of the shares subject to the option vested one year after the date of grant, on 11/8/2022, and the remaining 1/36 of the shares vest on a monthly basis thereafter.
F6: 1/4 of the shares subject to the option vested one year after the date of grant, on 2/24/2023, and the remaining 1/36 of the shares vest on a monthly basis thereafter.
SANGAMO THERAPEUTICS, INC
Report date June 11, 2018 · Filed June 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,332 |
Reported balance
After 2018-06-11 transaction · row 1
1 source rowRow 1 · 2018-06-11 · Grant · Acquired 2,500 · Balance 14,332 F1: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.65 · Expires 2028-06-10 | Direct | 15,000 |
Reported balance
After 2018-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-11 · Grant · Acquired 15,000 · Balance 15,000 F3: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 32,214 |
Reported balance
Holding disclosure · report date 2018-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 32,214 F2: These shares are held by Steven J. Mento and Linda A. Mento, Trustees of the Mento Family Trust dated December 29, 1994. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
F2: These shares are held by Steven J. Mento and Linda A. Mento, Trustees of the Mento Family Trust dated December 29, 1994.
F3: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001493152-26-000695 · ownership.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 23:50 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001654954-25-000397 · section16.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-01-12 F1 · derivative.exercise_date: The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date. Read SEC document |
| January 04, 2024 Filed Jan 6, 2024 02:04 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001654954-24-000300 · section16.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-03 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing January 4, 2024. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:32 UTC | Histogen Inc. HSTO · Entity 112047 | Disposition to issuerStock Option (right to buy) · Derivative | 7,582 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001209191-23-018474 · doc4.xml · derivative · entry 4 Mento Steven J · CIK 0001324466 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,582 shares Expires 2032-02-24 F3 · derivative.exercise_price: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share. F4 · kind: On March 10, 2023, the Issuer and the Reporting Person agreed to cancel the stock option award. F3 · shares: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share. F6 · derivative.exercise_date: 1/4 of the shares subject to the option vested one year after the date of grant, on 2/24/2023, and the remaining 1/36 of the shares vest on a monthly basis thereafter. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:32 UTC | Histogen Inc. HSTO · Entity 112047 | Disposition to issuerStock Option (right to buy) · Derivative | 18,892 | $0.00 Strike: $14.60 | $0.00 |
DisclosureSEC source: 0001209191-23-018474 · doc4.xml · derivative · entry 3 Mento Steven J · CIK 0001324466 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,892 shares Expires 2031-11-08 F3 · derivative.exercise_price: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share. F4 · kind: On March 10, 2023, the Issuer and the Reporting Person agreed to cancel the stock option award. F3 · shares: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share. F5 · derivative.exercise_date: 1/4 of the shares subject to the option vested one year after the date of grant, on 11/8/2022, and the remaining 1/36 of the shares vest on a monthly basis thereafter. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:32 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 55,532 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001209191-23-018474 · doc4.xml · derivative · entry 2 Mento Steven J · CIK 0001324466 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,532 Underlying: Common Stock · 55,532 shares Expires 2033-03-10 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest one year after the date of grant, on 3/10/2024, and the remaining 1/36 of the shares vest on a monthly basis thereafter. F2 · derivative.exercise_date: The shares subject to this option are subject to forfeiture in the event that the shares available pursuant to the Issuer's 2020 Incentive Award Plan are not increased prior to the one-year anniversary and vesting of the award by an amount required to be available for issuance for all outstanding stock awards containing this forfeiture condition. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 16:32 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 158,055 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001209191-23-018474 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,055 Underlying: Common Stock · 158,055 shares Expires 2033-03-10 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest one year after the date of grant, on 3/10/2024, and the remaining 1/36 of the shares vest on a monthly basis thereafter. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 16:29 UTC | Histogen Inc. HSTO · Entity 112047 | Disposition to issuerRestricted Stock Units · Derivative | 11,419 | $250.00 | $2,854,750.00 |
DisclosureSEC source: 0001209191-22-056212 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director · Interim President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,419 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · kind: On November 7, 2022, the Issuer and the Reporting Person agreed to cancel the restricted stock unit award prior to the vesting of such award in exchange for cash. F3 · shares: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share. F4 · derivative.exercise_date: The restricted stock unit award was cancelled as of November 7, 2022 prior to any vesting or exercisability thereof. F4 · derivative.expiration_date: The restricted stock unit award was cancelled as of November 7, 2022 prior to any vesting or exercisability thereof. F3 · derivative.underlying_shares: Effective June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share. Read SEC document |
| February 24, 2022 Filed Feb 25, 2022 16:40 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 151,642 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001209191-22-013211 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director · Interim President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,642 Underlying: Common Stock · 151,642 shares Expires 2032-02-24 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest one year after the date of grant, on 2/24/2023, and the remaining 1/36 of the shares vest on a monthly basis thereafter. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:03 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0000905718-22-000042 · dermata_fm4jan32022.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-01-02 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing January 3, 2022. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 16:46 UTC | Histogen Inc. HSTO · Entity 112047 | GrantRestricted Stock Unit · Derivative | 228,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-063872 · doc4.xml · derivative · entry 2 Mento Steven J · CIK 0001324466 · Director · Interim President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,395 Underlying: Common Stock · 228,395 shares Expires 2031-11-08 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: One hundred percent of the restricted stock units will vest upon the earlier to occur of (i) one (1) year after the grant date, or (ii) the Issuer's hiring of a permanent Chief Executive Officer and President, subject to the Reporting Person's continuing to provide services to Issuer through the relevant vesting dates. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 16:46 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 377,830 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-21-063872 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director · Interim President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,830 Underlying: Common Stock · 377,830 shares Expires 2031-11-08 F1 · derivative.exercise_date: Twenty-five percent (25%) of the option award shall vest on the annual anniversary of the option award so that one hundred percent (100%) of the option award shall vest by the fourth anniversary of the grant date, subject to the Reporting Person continuing to provide services to Issuer through the relevant vesting dates. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 16:08 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001209191-21-054741 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-02 F1 · shares: This option was issued to the Reporting Person, a non-employee director of the Issuer, for his service as a director of the Issuer. F2 · derivative.exercise_date: The shares subject to this option become fully vested and exercisable on 5/26/2022, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 16:52 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | GrantStock Option (right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001114 · dermata_fm4aug172021.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing September 17, 2021. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 16:12 UTC | Histogen Inc. HSTO · Entity 112047 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-20-054437 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-10-07 F1 · shares: This option was issued to the Reporting Person, a non-employee director of the Issuer, for his service as a director of the Issuer. F2 · derivative.exercise_date: The shares subject to this option become fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 22, 2020 Filed May 27, 2020 06:04 UTC | Histogen Inc. HSTO · Entity 112047 | Exercise / conversionRestricted Stock Units · Derivative | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014288 · doc4.xml · derivative · entry 4 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among Conatus Pharmaceuticals Inc. ("Conatus"), Chinook Merger Sub, Inc. and Histogen Inc., all outstanding Conatus restricted stock units vested in full and were settled in shares of common stock prior to the closing of the merger contemplated by the Merger Agreement. F3 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among Conatus Pharmaceuticals Inc. ("Conatus"), Chinook Merger Sub, Inc. and Histogen Inc., all outstanding Conatus restricted stock units vested in full and were settled in shares of common stock prior to the closing of the merger contemplated by the Merger Agreement. Read SEC document |
| May 22, 2020 Filed May 27, 2020 06:04 UTC | Histogen Inc. HSTO · Entity 112047 | Tax withholdingCommon Stock | 31,428 | $0.56 | $17,599.68 |
DisclosureSEC source: 0000899243-20-014288 · doc4.xml · nonDerivative · entry 2 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,572 Read SEC document |
| May 22, 2020 Filed May 27, 2020 06:04 UTC | Histogen Inc. HSTO · Entity 112047 | Exercise / conversionCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014288 · doc4.xml · nonDerivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | GrantRestricted Stock Units · Derivative | 650,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 9 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires not disclosed F14 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F15 · shares: Represents 200,000 restricted stock units received in exchange for canceling the Reporting Person's option granted on February 7, 2014; 100,000 restricted stock units received in exchange for canceling the Reporting Person's options granted on February 23, 2015; 10,000 restricted stock units received in exchange for canceling the Reporting Person's option granted on February 4, 2016; 18,750 restricted stock units received in exchange for canceling the Reporting Person's option granted on February 4, 2016; 86,250 restricted stock units received in exchange for canceling the Reporting Person's option granted on January 26, 2017; 60,000 restricted stock units received in exchange for canceling the Reporting Person's option granted on February 4, 2018; and 175,000 restricted stock units received in exchange for canceling the Reporting Person's option granted on February 7, 2019. F16 · derivative.exercise_date: The restricted stock units will vest, subject to the Reporting Person's continuous service to the Issuer through the vesting date, on the first anniversary of the grant date. In addition, the restricted stock units will vest upon a Change of Control, an employee's termination without Cause, or resignation for Good Reason, as such terms are defined in the Issuer's 2013 Incentive Award Plan. Upon any other termination of service of the Reporting Person, unvested restricted stock units will be forfeited. F16 · derivative.expiration_date: The restricted stock units will vest, subject to the Reporting Person's continuous service to the Issuer through the vesting date, on the first anniversary of the grant date. In addition, the restricted stock units will vest upon a Change of Control, an employee's termination without Cause, or resignation for Good Reason, as such terms are defined in the Issuer's 2013 Incentive Award Plan. Upon any other termination of service of the Reporting Person, unvested restricted stock units will be forfeited. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | Disposition to issuerStock Option (Right to Buy) · Derivative | 350,000 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 8 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires 2029-02-06 F13 · price: On August 1, 2019, the Issuer canceled the option granted on February 7, 2019. In exchange for the canceled option, the Reporting Person received 175,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F12 · derivative.exercise_date: The option was granted on February 7, 2019. 25% of the total number of shares of common stock subject to the option will vest on February 7, 2020, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | Disposition to issuerStock Option (Right to Buy) · Derivative | 120,000 | Not disclosed Strike: $5.17 | Not disclosed |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 7 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires 2028-02-03 F11 · price: On August 1, 2019, the Issuer canceled the option granted on February 4, 2018. In exchange for the canceled option, the Reporting Person received 60,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F10 · derivative.exercise_date: The option was granted on February 4, 2018. 25% of the total number of shares of common stock subject to the option vested on February 2, 2019, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | Disposition to issuerStock Option (Right to Buy) · Derivative | 172,500 | Not disclosed Strike: $4.21 | Not disclosed |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 6 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 172,500 shares Expires 2027-01-25 F9 · price: On August 1, 2019, the Issuer canceled the option granted on January 26, 2017. In exchange for the canceled option, the Reporting Person received 86,250 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The option was granted on January 26, 2017. 25% of the total number of shares of common stock subject to the option vested on January 26, 2018, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | Disposition to issuerStock Option (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 5 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2026-02-03 F7 · price: On August 1, 2019, the Issuer canceled the option granted on February 4, 2016. In exchange for the canceled option, the Reporting Person received 18,750 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 4 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-02-03 F6 · price: On August 1, 2019, the Issuer canceled the option granted on February 4, 2016. In exchange for the canceled option, the Reporting Person received 10,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The option was granted on February 4, 2016. 25% of the total number of shares of common stock subject to the option vested on February 4, 2017, and 1/48th of the total number of shares of common stock subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $6.40 | Not disclosed |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 3 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-02-22 F4 · price: On August 1, 2019, the Issuer canceled the option granted on February 23, 2015. In exchange for the canceled option, the Reporting Person received 25,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | Disposition to issuerStock Option (Right to Buy) · Derivative | 150,000 | Not disclosed Strike: $6.40 | Not disclosed |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 2 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2025-02-22 F3 · price: On August 1, 2019, the Issuer canceled the option granted on February 23, 2015. In exchange for the canceled option, the Reporting Person received 75,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 16:11 UTC | Histogen Inc. CNAT · Entity 112047 | Disposition to issuerStock Option (Right to Buy) · Derivative | 400,000 | Not disclosed Strike: $9.45 | Not disclosed |
DisclosureSEC source: 0001209191-19-044008 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2024-02-06 F2 · price: On August 1, 2019, the Issuer canceled the option granted on February 7, 2014. In exchange for the canceled option, the Reporting Person received 200,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:14 UTC | Histogen Inc. CNAT · Entity 112047 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008917 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2029-02-06 F1 · derivative.exercise_date: The option was granted on February 7, 2019. 25% of the total number of shares of common stock subject to the option will vest on February 6, 2020, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:26 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001209191-18-037347 · doc4.xml · derivative · entry 3 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-10 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:26 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037347 · doc4.xml · nonDerivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,332 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 04, 2018 Filed May 7, 2018 19:46 UTC | Histogen Inc. CNAT · Entity 112047 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-18-028454 · doc4.xml · derivative · entry 3 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,070 Underlying: Common Stock · 60,000 shares Expires 2021-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2018 Filed May 7, 2018 19:46 UTC | Histogen Inc. CNAT · Entity 112047 | Exercise / conversionCommon Stock | 60,000 | $0.99 | $59,400.00 |
DisclosureSEC source: 0001209191-18-028454 · doc4.xml · nonDerivative · entry 1 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-023598 · doc4.xml · derivative · entry 5 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2023-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 100 | $18.90 | $1,890.00 |
DisclosureSEC source: 0001209191-18-023598 · doc4.xml · nonDerivative · entry 3 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,832 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2017. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 7,115 | $18.39 | $130,868.33 |
DisclosureSEC source: 0001209191-18-023598 · doc4.xml · nonDerivative · entry 2 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,932 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2017. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $17.85 to $18.85 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:10 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 10,000 | $7.77 | $77,700.00 |
DisclosureSEC source: 0001209191-18-023598 · doc4.xml · nonDerivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:50 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStockOption (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-18-016894 · doc4.xml · derivative · entry 6 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:50 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001209191-18-016894 · doc4.xml · derivative · entry 5 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:50 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 9,433 | $23.27 | $219,546.47 |
DisclosureSEC source: 0001209191-18-016894 · doc4.xml · nonDerivative · entry 3 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,047 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2017. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $22.55 to $24.05 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:50 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 10,000 | $5.03 | $50,300.00 |
DisclosureSEC source: 0001209191-18-016894 · doc4.xml · nonDerivative · entry 2 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 23:50 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $6.41 | $32,050.00 |
DisclosureSEC source: 0001209191-18-016894 · doc4.xml · nonDerivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2018 Filed Feb 5, 2018 16:57 UTC | Histogen Inc. CNAT · Entity 112047 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001209191-18-007553 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2028-02-03 F1 · derivative.exercise_date: The option was granted on February 4, 2018. 25% of the total number of shares of common stock subject to the option will vest on February 2, 2019, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStockOption (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.17 | $0.00 |
DisclosureSEC source: 0001209191-18-007711 · doc4.xml · derivative · entry 6 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.41 | $0.00 |
DisclosureSEC source: 0001209191-18-007711 · doc4.xml · derivative · entry 5 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2021-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | SaleCommon Stock | 11,520 | $20.59 | $237,158.78 |
DisclosureSEC source: 0001209191-18-007711 · doc4.xml · nonDerivative · entry 3 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,480 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2017. F2 · price: The price reported is a weighted average price. The shares were sold at prices ranging from $20.25 to $20.90 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 10,000 | $10.17 | $101,700.00 |
DisclosureSEC source: 0001209191-18-007711 · doc4.xml · nonDerivative · entry 2 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | Exercise / conversionCommon Stock | 5,000 | $6.41 | $32,050.00 |
DisclosureSEC source: 0001209191-18-007711 · doc4.xml · nonDerivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 22:01 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001140361-17-024393 · doc1.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-04 F1 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vest in monthly installments upon completion of each month of Board service over a one year period. Read SEC document |
| January 26, 2017 Filed Feb 1, 2017 16:20 UTC | Histogen Inc. CNAT · Entity 112047 | GrantStock Option (Right to Buy) · Derivative | 172,500 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-17-006682 · doc4.xml · derivative · entry 1 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,500 Underlying: Common Stock · 172,500 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option was granted on January 26, 2017. 25% of the total number of shares of common stock subject to the option will vest on January 26, 2018, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| December 20, 2016 Filed Dec 22, 2016 16:04 UTC | Histogen Inc. CNAT · Entity 112047 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,051 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-16-156476 · doc4.xml · derivative · entry 5 Mento Steven J · CIK 0001324466 · Director · President, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,070 Underlying: Common Stock · 5,051 shares Expires 2021-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.